<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="research-article"><?properties open_access?><!-- Original-type: ra--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">11027423</article-id><article-id pub-id-type="pmc">2363577</article-id><article-id pub-id-type="pii">6691425</article-id><article-id pub-id-type="doi">10.1054/bjoc.2000.1425</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Article</subject></subj-group></article-categories><title-group><article-title>A randomized trial of 13-Cis retinoic acid in children with advanced neuroblastoma after high-dose therapy</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kohler</surname><given-names>J A</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Imeson</surname><given-names>J</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Ellershaw</surname><given-names>C</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Lie</surname><given-names>S O</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Child Health, Southampton General Hospital, Southampton, SO16 6YD</aff><aff id="aff2"><label>2</label>United Kingdom Children&#x02019;s Cancer Study Group, Department of Epidemiology and Public Health, University of Leicester, 22&#x02013;28 Princess Road West, Leicester, LE1 6TP</aff><aff id="aff3"><label>3</label>Department of Pediatrics, The National Hospital, Pilestredet 32, Oslo, N-0027, Norway</aff><pub-date pub-type="ppub"><month>11</month><year>2000</year></pub-date><volume>83</volume><issue>9</issue><fpage>1124</fpage><lpage>1127</lpage><history><date date-type="received"><day>12</day><month>10</month><year>1999</year></date><date date-type="rev-recd"><day>12</day><month>05</month><year>2000</year></date><date date-type="accepted"><day>08</day><month>07</month><year>2000</year></date></history><copyright-statement>Copyright 2000, Cancer Research Campaign</copyright-statement><copyright-year>2000</copyright-year><permissions><copyright-holder>Cancer Research Campaign</copyright-holder></permissions><abstract><p>One hundred and seventy-five children with Stage 3 or 4 neuroblastoma who had obtained a good response to conventional therapy were randomly allocated to 13-Cis retinoic acid at a dose of 0.75&#x02009;mg/kg/day or placebo for up to 4 years. Toxicity was mild but no advantage in event-free survival was shown for the children receiving retinoic acid. &#x000a9; 2000 Cancer Research Campaign</p></abstract><kwd-group><kwd>13-Cis retinoic acid</kwd><kwd>neuroblastoma</kwd></kwd-group></article-meta></front></article>


